Article
Journal of Medicinal Chemistry, 2009, Vol. 52, No. 17 5461
(6) Paterson, J. M.; Morton, N. M.; Fievet, C.; Kenyon, C. J.; Holmes,
M. C.; Staels, B.; Seckl, J. R.; Mullins, J. J. Metabolic syndrome
without obesity: hepatic overexpression of 11β-hydroxysteroid
dehydrogenase type 1 in transgenic mice. Proc. Natl. Acad. Sci.
U.S.A. 2004, 101, 7088–7093.
(7) Morton, N. M.; Paterson, M.; Masuzaki, H.; Holmes, M.; Staels,
B.; Fievet, C.; Walker, B.; Flier, J. S.; Mullins, J. J.; Seckl, J. R.
Novel adipose tissue- mediated resistance to diet-induced visceral
obesity in 11β-hydroxysteroid dehydrogenase type-1 deficient
mice. Diabetes 2004, 53, 931–938.
B.; Abrahmsen, L. Selective inhibition of 11β-hydroxysteroid dehy-
drogenase type 1 decreases blood glucose concentrations in hypergly-
caemic mice. Diabetologia 2002, 45, 1528–1532. (c) Alberts, P.;
Nilsson, C.; Selen, G.; Engblom, L. O.; Edling, N. H.; Norling, S.;
Klingstrom, G.; Larsson, C.; Forsgren, M.; Ashkzari, M.; Nilsson, C. E.;
Fiedler, M.; Bergqvist, E.; Ohman, B.; Bjorkstrand, E.; Abrahmsen, L.
B. Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1
improves hepatic insulin sensitivity in hyperglycemic mice strains.
Endocrinology 2003, 144, 4755–4762.
(10) Rueckle, T.; Vitte, P. A.; Gotteland, J. P. WO Patent 2005025558, 2005.
(11) Hermanowski-Vosatka, A.; Balkovec, J. M.; Cheng, K.; Chen,
H. Y.;Hernandez, G. C.;Koo, G. C.;LeGrand, C. B.;Li, Z.;Metzger,
M. M.; Mundt, S. S.; Noonan, H.; Nunes, C. N.; Olson, S. H.;
Pikounis, B.; Ren, N.; Robertson, N.; Schaeffer, M. M.; Shah, K.;
Springer, M. S.; Strack, A. M.; Strowski, M.; Wu, K.; Wu, T.; Xiao,
J.; Zhang, B. B.; Wright, S. D.; Thieringer, R. 11β-HSD1 inhibition
ameliorates metabolic syndrome and prevents progression of
atherosclerosis in mice. J. Exp. Med. 2005, 202, 517–527.
(12) Hoff, E. D.; Link, J. T.; Pliushchev, M. M.; Rohde, J. J.; Winn, M.
U.S. Patent 20050245533, 2005.
(13) Yeh, V. S. C.; Kurukulasuriya, R.; Fung, S.; Monzon, K.; Chiou,
W.; Wan, J.; Stolarik, D.; Imade, H.; Shapiro, R.; Knoure-Segel,
V.; Bush, E.; Wilcox, D.; Nguyen, H. T.; Brune, M.; Jacobson, P.;
Link, J. T. Discovery of orally active butyrolactam 11β-HSD1
inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 5555–5560.
(14) Bhat, B. G.; Hosea, N.; Fanjul, A.; Herrera, J.; Chapman, J.;
Thalacker, F.; Stewart, P. M.; Rejto, P. A. Demonstration of proof
of mechanism and pharmacokinetics and pharmacodynamic rela-
tionship with 40-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-
2-yl)-amide (PF-915275), an inhibitor of 11β-hydroxysteroid de-
hydrogenase type 1, in cynomolgus monkeys. J. Pharmacol. Exp.
Ther. 2008, 324, 299–305.
(15) Xiang, J.; Wan, Z.-K.; Li, H.-Q.; Ipek, M.; Binnun, E.; Nunez, J.;
Chen, L.; McKew, J. C.; Mansour, T. S.; Xu, X.; Suri, V.; Tam, M.;
Xing, Y.; Li, X.; Hahm, S.; Tobin, J.; Saiah, E. Piperazine
sulfonamides as potent, selective, and orally available 11β-hydro-
xysteroid dehydrogenase type 1 inhibitors with efficacy in the rat
cortisone-induced hyperinsulinemia model. J. Med. Chem. 2008,
51, 4068–4071.
(16) (a) Wagaw, S.; Buchwald, S. L. The synthesis of aminopyridines: a
method employing palladium-catalyzed carbon-nitrogen bond for-
mation. J. Org. Chem. 1996, 61, 7240–7241. (b) Old, D. W.; Wolfe,
J. P.; Wagaw, S.; Marcoux, J.-F.; Buchwald, S. L. Rational development
of practical catalysts for aromatic carbon-nitrogen bond formation. Acc.
Chem. Res. 1998, 31, 805–818.
(8) For a review, see: (a) Saiah, E. The role of 11beta-hydroxysteroid
dehydrogenase in metabolic disease and therapeutic potential of
11beta-HSD1 inhibitors. Curr. Med. Chem. 2008, 15, 642–649Re-
cently reported 11β-HSD1 inhibitors: . (b) Sun, D.; Wang, Z.; Di, Y.;
Jaen, J. C.; Labelle, M.; Ma, J.; Miao, S.; Sudom, A.; Tang, L.; Tooka, C.
S.; Tu, H.; Ursu, S.; Walker, N.; Yan, X.; Ye, Q.; Powers, J. P. Discovery
and Initial SAR of Arylsulfonylpiperazine Inhibitors of 11β-Hydro-
xysteroid Dehydrogenase Type 1 (11β-HSD1). Bioorg. Med. Chem.
Lett. 2008, 18, 3513–3516. (c) Aster, S. D.; Graham, D. W.; Kharbanda,
D.; Patel, G.; Ponpipom, M.; Santorelli, G. M.; Szymonifka, M. J.;
Mundt, S. S.; Shah, K.; Springer, M. S.; Thieringer, R.; Hermanowski-
Vosatka, A.; Wright, S. D.; Xiao, J.; Zokian, H.; Balkovec, J. M. Bis-
aryl triazoles as selective inhibitors of 11β-hydroxysteroid dehydro-
genase type 1. Bioorg. Med. Chem. Lett. 2008, 18, 2799–2804. (d) St.
Jean, D. J.; Yuan, C.; Bercot, E. A.; Cupples, R.; Chen, M.; Fretland, J.;
Hale, C.; Hungate, R. W.; Komorowski, R.; Veniant, M.; Wang, M.;
Zhang, X.; Fotsch, C. 2-(S)-Phenethylaminothiazolones as potent,
orally efficacious inhibitors of 11β-hydroxysteroid dehydrogenase type 1.
J. Med. Chem. 2007, 50, 429–432. (e) Rohde, J. J.; Pliushchev, M. A.;
Sorensen, B. K.; Wodka, D.; Shuai, Q.; Wang, J.; Fung, S.; Monzon, K.
M.; Chiou, W. J.; Pan, L.; Deng, X.; Chovan, L. E.; Ramaiya, A.;
Mullally, M.; Henry, R. F.; Stolarik, D. F.; Imade, H. M.; Marsh, K. C.;
Beno, D. W. A.; Fey; Thomas, A.; Droz, B. A.; Brune, M. E.; Camp,
H. S.; Sham, H. L.; Frevert, E. U.; Jacobson, P. B.; Link, J. T. Discovery
and metabolic stabilization of potent and selective 2-amino-
N-(adamant-2-yl)acetamide 11β-hydroxysteroid dehydrogenase type 1
inhibitors. J. Med. Chem. 2007, 50, 149–164. (f) Xiang, J.; Ipek, M.;
Suri, V.; Tam, M.; Xing, Y.; Huang, N.; Zhang, Y.; Tobin, J.; Mansour,
T.; McKew, J. β-Keto sulfones as inhibitors of 11β-hydroxysteroid
dehydrogenase type 1 and the mechanism of action. Bioorg. Med.
Chem. 2007, 15, 4396–4405. (g) Sorensen, B.; Winn, M.; Rohde, J.;
Shuai, Q.; Wang, J.; Fung, S.; Monzon, K.; Chiou, W.; Stolarik, D.;
Imade, H.; Pan, L.; Deng, X.; Chovan, L.; Longenecker, K.; Judge, R.;
Qin, W.; Brune, M.; Camp, H.; Frevert, E. U.; Jackbson, P.; Link, J. T.
Adamantane sulfone and sulfonamide 11β-HSD1 inhibitors. Bioorg.
Med. Chem. Lett. 2007, 17, 527–32. (h) Yeh, V.; Kurukulasuriya, R.;
Madar, D.; Patel, J.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.;
Jacobson, P.; Sham, H.; Link, J. Synthesis and structural activity
relationship of 11β-HSD1 inhibitors with novel adamantane replace-
ments. Bioorg. Med. Chem. Lett. 2006, 16, 5408–5413. (i) Schuster,
D.; Maurer, E.; Laggner, C.; Nashev, L.; Wilckens, T.; Langer, T.;
Odermatt, A. The discovery of new 11β-hydroxysteroid dehydrogenase
type 1 inhibitors by common feature pharmacophore modeling and
virtual screening. J. Med. Chem. 2006, 49, 3454–3466. (j) Gu, X.;
Dragovic, J.; Koo, G. C.; Koprak, S. L.; LeGrand, C.; Mundt, S. S.;
Shah, K.; Springer, M.; Tan, E.; Thieringer, R.; Hermanowski- Vosatka,
A.; Zokian, H.; Balkovec, J.; Waddell, S. T. Discovery of 4-
heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors
of 11β-HSD1: Novel therapeutic agents for the treatment of metabolic
syndrome. Bioorg. Med. Chem. Lett. 2005, 15, 5266–5269. (k) Olson,
S.; Aster, S.; Brown, K.; Carbin, L.; Graham, D.; Hermanowski, A.;
LeGrand, C.; Mundt, S.; Robbins, M.; Schaeffer, J.; Slossberg, L.;
Szymonifka, M.; Thieringer, R.; Wright, S.; Balkovec, J. Adamantyl
triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase
type 1. Bioorg. Med. Chem. Lett. 2005, 15, 4359–4362. (l) Xiang, J.;
Ipek, M.; Suri, V.; Massefski, W.; Pan, N.; Ge, Y.; Tam, M.; Xing, Y.;
Tobin, J.; Xu, X.; Tam, S. Synthesis and biological evaluation of
sulfonamidooxazoles and β-keto sulfones: selective inhibitors of 11β-
hydroxysteroid dehydrogenase type I. Bioorg. Med. Chem. Lett. 2005,
15, 2865–2869. (m) Coppola, G.; Kukkola, P.; Stanton, J.; Neubert, A.;
Marcopulos, N.; Bilci, N.; Wang, H.; Tomaselle, H.; Tan, J.; Aicher, T.;
Knorr, D.; Jeng, A.; Dardik, B.; Chatelain, R. Perhydroquinolylbenza-
mides as novel inhibitors of 11β-hydroxysteroid dehydrogenase type 1.
J. Med. Chem. 2005, 48, 6696–6712.
(17) (a) Mune, T.; Rogerson, F. M.; Nikkila, H.; Agarwal, A. K.; White,
P. C. Human hypertension caused by mutations in the kidney
isoenzyme of 11β-hydroxysteroid dehydrogenase. Nat. Genet.
1995, 10, 394–399. (b) Dave-Sharma, S.; Wilson, R. C.; Harbison,
M. D.; Newfield, R.; Azar, M. R.; Krozowski, Z. S.; Funder, J. W.;
Shackleton, C. H. L.; Bradlow, H. L.; Wei, J.-Q.; Hertecant, J.; Moran,
A.; Neiberger, R. E.; Balfe, J. W.; Fattah, A.; Daneman, D.; Akkurt,
H. I.; De Santis, C.; New, M. I. Examination of genotype and phenotype
relationships in 14 patients with apparent mineralocorticoid excess.
J. Clin. Endocrinol. Metab. 1998, 83, 2244–2254.
(18) Manuscript is under preparation.
(19) Adam, T. C.; Epel, E. S. Stress, eating and the reward system.
Physiol. Behav. 2007, 91, 449–458.
(20) Lambillotte, C.; Gilon, P.; Henquin, J. C. Direct glucocorticoid
inhibition of insulin secretion. An in vitro study of dexamethasone
effects in mouse islets. J. Clin. Invest. 1997, 99, 414–423.
(21) Hosfield, D. J.; Wu, Y.; Skene, R. J.; Hilgers, M.; Jennings, A.;
Snell, G. P.; Aertgeerts, K. Conformational flexibility in crystal
structures of human 11β-hydroxysteroid dehydrogenase type I
provide insights into glucocorticoid interconversion and enzyme
regulation. J. Biol. Chem. 2005, 280, 4639–4648.
(22) Otwinowski, Z.; Minor, W. Processing of X-ray Diffraction Data
Collected in Oscillation Mode. Methods Enzymol 1997, 276, 307–326.
(23) Adams, P. D.; Grosse-Kunstleve, R. W.; Hung, L.-W.; Ioerger, T.
R.; McCoy, A. J.; Moriarty, N. W.; Read, R. J.; Sacchettini, J. C.;
Sauter, N. K.; Terwilliger, T. C. PHENIX: building new software
for automated crystallographic structure determination. Acta
Crystallogr., Sect. D: Biol. Crystallogr. 2002, 58, 1948–1954.
(24) Emsley, P.; Cowtan, K. Coot: model-building tools for molecular
graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60,
2126–2132.
(25) Lovell, S. C.; Davis, I. W.; Arendall, W. B., III; de Bakker, P. I. W.;
Word, J. M.; Prisant, M. G.; Richardson, J. S.; Richardson, D. C.
Structure validation by CR geometry: j, ψ, and Cβ deviation.
Proteins: Structure, Function, and Genetics 2003, 50, 437–450.
(26) DeLano, W. L. The PyMOL User0s Manual; DeLano Scientific: Palo
Alto, CA, 2002.
(9) (a) Barf, T.; Vallgarda, J.; Emond, R.; Haggstrom, C.; Kurz, G.;
Nygren, A.; Larwood, V.; Mosialou, E.; Axelsson, K.; Olsson, R.;
Engblom, L.; Edling, N.; Ronquist-Nii, Y.; Ohman, B.; Alberts, P.;
Abrahmsen, L. Arylsulfonamidothiazoles as a new class of poten-
tial antidiabetic drugs: discovery of potent and selective inhibitors
of the 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem.
2002, 45, 3813–3815. (b) Alberts, P.; Engblom, L.; Edling, N.;
Forsgren, M.; Klingstrom, G.; Larsson, C.; Ronquist-Nii, Y.; Ohman,